Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

European Journal of Heart Failure

Volumn 4, Issue 5, 2002, Pages 583-586

  Vaynblat, Mikhail ^a   Shah, Himansu R ^b   Bhaskaran, Dinesh ^a   Ramdev, Geeta ^b   Davis Iii, Wellington J ^a   Cunningham Jr, Joseph N ^a,b   Chiavarelli, Mario ^b  

^a Admin Building   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Cardiomyopathy; Dog; Heart failure; Ventricular function

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DOG; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE WORK; HEART PROTECTION; HEART RIGHT VENTRICLE VOLUME; HEMODYNAMICS; INTRACORONARY INFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOGS; DOXORUBICIN; ENALAPRIL; HEART FAILURE, CONGESTIVE; HEART RATE; MALE; MODELS, CARDIOVASCULAR; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036803013     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00091-0     Document Type: Article

References (21)

1. Yusuf S. Effect of enalparil on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. New Engl J Med 1991;325:293-302.
2. Ritchie JL, Cheitlin MD, Eagle KA, et al. Guidelines for the evaluation and management of heart failure; report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
3. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 1992;327:669-77.
4. The SOLVD Investigators. Effect of captopril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1992;327:685-91.
5. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart. A concise review. J Mol Cell Cardiol 1987;19:817-28.
6. Vaynblat M, Chiavarelli M, Shah HR, et al. Cardiac binding in experimental heart failure. Ann Thorac Surg 1997;64:81-6.
7. Shah HR, Vaynblat M, Ramdev G, Cunningham JN, Chiavarelli M. Experimental cardiomyopathy as a model of chronic heart failure. J Invest Surg 1997;10:387-96.
8. Wyatt H, Heng MK, Meerbaum S, et al. Cross-sectional echocardiography 1. Analysis of mathematic models for quantifying mass of the left ventricle in dogs. Circulation 1979;60:1104.
9. Magovern JA, Christlieb IY, Badylak SF, Lantz GC, Kao RL. A model of left ventricular dysfunction caused by intracoronary doxorubicin. Ann Thorac Surg 1992;53:861-3.
10. Porta EA, Joun NS, Matsumura L, Nakasone B, Sablan H. Acute adriamycin cardiotoxicity in rats. Res Comm Path Pharmac 1983;41:125-37.
11. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817-28.
12. Yin X, Wu H, Chen Y, Kang YJ. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998;56:87-93.
13. Pfeffer J, Pfeffer M, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
14. Raya TE, Gay RG, Aguirre M, Goldman S. Importance of venodilation in prevention of left ventricular dilation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazine. Circ Res 1989;64:330-3.
15. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: An appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-21.
16. Daly P, Rouleau JL, Cousineau D, Burgess JH. Acute effects of captopril on the coronary circulation of patients with hypertension and angina. Am J Med 1984;76(5B):111.
17. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptotic patients with reduced left ventricular ejections fractions. N Engl Med 1992;327:685-91.
18. The CONSENSUS Trial study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
19. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
20. Kakavas PW, Ghalie R, Parrillo JE, Kaizer H, Barron JT. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant 1995;15:859-61.
21. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.